SAN DIEGO, Jan. 07, 2016 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) is pleased to announce its Chief Executive Officer, Ms. Reggie Groves, is scheduled to present at the 34th Annual J.P. Morgan Healthcare Conference at 9:30 a.m. US PST on Thursday, January 14, 2016. The conference is being held January 11th through 14th at The Westin St. Francis Hotel in San Francisco, California.
The presentation materials delivered at the conference will be available in the Investor Relations section of REVA’s website at www.revamedical.com on the day of the presentation. A copy of the presentation materials will also be lodged with the Australian Securities Exchange and filed with the U.S. Securities and Exchange Commission.
About REVA
REVA is a clinical stage medical device company located in San Diego, California, USA, that is working to commercialize its proprietary bioresorbable stents, which are called “scaffolds” because of their temporary nature. The Company’s scaffolds have been developed as an alternative to metal stents, which are small tube-like devices permanently implanted into an artery to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company’s initial product, the Fantom® scaffold, has been designed to offer an ideal balance of thinness and strength and distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations. REVA will require successful clinical trial results and regulatory approval before it can commercialize Fantom or any other products.
United States Investor & Media Enquiries: REVA Medical, Inc. Cheryl Liberatore Director, Communications +1 858-966-3045 Australia Investor Enquiries: Inteq Limited Kim Jacobs +61 2 9229 2700 Australia Media Enquiries: Buchan Consulting Rebecca Wilson +61 3 9866 4722 Annabel Murphy +61 2 9237 2800


TSMC Japan's Second Fab to Produce 3nm Chips by 2028
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 



